Question: Does anyone know if a pharma who wants t
Post# of 30066
Posted On: 12/29/2014 1:41:52 PM
Question: Does anyone know if a pharma who wants to use Lympro to screen their clinical trial patients.....must submit Lympro in their plan to the FDA before they can use us, or do they have the discretion to use us without submitting us to the FDA?
The answer to that question will determine just how fast revenue actually starts coming in. There may be a 3 to 6 month delay from the time a pharma commits to using us from the time when they actually do use us and pay us for it.
I hope Gerald is able to inform us that pharmas are actually committing to use us rather than just saying they are having great conversations with them.
At this point I think the data is becoming less significant. Whether we are at 86 percent or 93 percent is kind of an academic pissing match. The point is.... at 86 percent we are as accurate as the screening tool they're using now, but one third the cost and far less invasive.
The important metric now isn't specificity and sensitivity, but rather the "acceptability" of Pharmas in using LymPro. I'm not exactly sure how Gerald will be able to convey that metric to us because a pharma may say "yes we intend to put Lympro into our plan," but until they do and the FDA approves their plan and they actually start using LymPro......they're just words.
In my opinion, how convinicingly Gerald is able to convey the "acceptability" of Lympro by pharmas is the most important factor in our stock price shooting up in January. Because with the promise of pharmas using Lympro means revenue will soon follow. And with revenue.....all the other drugs in our pipeline: Eltoprazine, ESS, MANF, and Phenoguard.....look that much more attractive.
The answer to that question will determine just how fast revenue actually starts coming in. There may be a 3 to 6 month delay from the time a pharma commits to using us from the time when they actually do use us and pay us for it.
I hope Gerald is able to inform us that pharmas are actually committing to use us rather than just saying they are having great conversations with them.
At this point I think the data is becoming less significant. Whether we are at 86 percent or 93 percent is kind of an academic pissing match. The point is.... at 86 percent we are as accurate as the screening tool they're using now, but one third the cost and far less invasive.
The important metric now isn't specificity and sensitivity, but rather the "acceptability" of Pharmas in using LymPro. I'm not exactly sure how Gerald will be able to convey that metric to us because a pharma may say "yes we intend to put Lympro into our plan," but until they do and the FDA approves their plan and they actually start using LymPro......they're just words.
In my opinion, how convinicingly Gerald is able to convey the "acceptability" of Lympro by pharmas is the most important factor in our stock price shooting up in January. Because with the promise of pharmas using Lympro means revenue will soon follow. And with revenue.....all the other drugs in our pipeline: Eltoprazine, ESS, MANF, and Phenoguard.....look that much more attractive.
(0)
(0)